Archives For March 2014

Biotech investment has rarely been hotter. After a decade of anemic public markets for startups, more than 70 life sciences companies have successfully gone public since the start of last year, raising nearly $2 billion in the process.

In analyzing how we got here, pundits inevitably offer the benefits of a strong overall stock market, spillover investing from huge profits made in technology or the positive impact of the Jobs Act for putting wind back into the sails of biotech investments.

But what if the answer is more primal? Or is something new and innovative contributing?

Continue Reading...